HILDEN, Germany, and GERMANTOWN, Maryland, January 23, 2018
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.
Click here for the full press release
Contacts: QIAGEN Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
Paralysis is a condition where there is a loss of muscle function as well as sensory loss, which ...
Swine flu, a type of influenza caused by a new strain of the H1N1 Type A influenza virus has ...
Body wraps is an all natural remedy to slenderizing & contouring your body that not just hydrate ...View All